Holen Sie sich die Stockscreener-App
38.88
0.79%
-0.31
Vorhandelsmarkt:
38.82
-0.06
-0.15%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TEVA?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$39.19
Offen:
$38.36
24-Stunden-Volumen:
4.20M
Relative Volume:
0.79
Marktkapitalisierung:
$45.35B
Einnahmen:
$17.53B
Nettoeinkommen (Verlust:
$1.58B
KGV:
28.89
EPS:
1.3457
Netto-Cashflow:
$444.18M
1W Leistung:
-2.95%
1M Leistung:
+6.70%
6M Leistung:
+35.28%
1J Leistung:
+112.00%
1-Tages-Spanne:
$38.30
$39.11
1-Wochen-Bereich:
$38.30
$40.31
52-Wochen-Spanne:
$18.47
$40.79
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile
Firmenname
Teva Pharmaceutical Industries Ltd Adr
Sektor
Telefon
972 (3) 914-8213
Adresse
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Compare TEVA vs TAK, HLN, ZTS, VTRS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
38.88 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
TAK
Takeda Pharmaceutical Co Adr
|
18.90 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.17 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.43 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
18.27 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-12-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-05-28 | Eingeleitet | Truist | Buy |
| 2025-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-07-10 | Hochstufung | Argus | Hold → Buy |
| 2024-03-08 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-12 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-01-23 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-11-27 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-06 | Hochstufung | UBS | Sell → Neutral |
| 2023-05-25 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-05-18 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-01-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-11-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-04 | Herabstufung | UBS | Neutral → Sell |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-08-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-06-14 | Fortgesetzt | UBS | Neutral |
| 2022-05-17 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-05-04 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-04-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-03-25 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-01-27 | Herabstufung | Argus | Buy → Hold |
| 2021-10-28 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-05-04 | Herabstufung | UBS | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2020-11-25 | Eingeleitet | Oppenheimer | Perform |
| 2020-08-06 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-07-27 | Fortgesetzt | Goldman | Neutral |
| 2020-06-01 | Hochstufung | SunTrust | Hold → Buy |
| 2020-04-24 | Fortgesetzt | Citigroup | Neutral |
| 2020-04-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-02-24 | Herabstufung | Edward Jones | Hold → Sell |
| 2019-11-12 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-10-17 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-08-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-07-19 | Eingeleitet | Wolfe Research | Peer Perform |
| 2019-07-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-07-10 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-07-05 | Hochstufung | Argus | Hold → Buy |
| 2019-06-11 | Eingeleitet | Barclays | Underweight |
| 2019-06-03 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-30 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-05-28 | Herabstufung | UBS | Buy → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2019-03-07 | Fortgesetzt | UBS | Buy |
Alle ansehen
Teva Pharmaceutical Industries Ltd Adr Aktie (TEVA) Neueste Nachrichten
Teva Pharmaceutical Industries Limited (TEVA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Teva Pharmaceutical Industries Limited (TEVA) stock price, news, quote and history - Yahoo Finance UK
Teva Releases Q3 2026 Aide Memoire - GlobeNewswire Inc.
Teva stock hits 52-week high at $39.71 - Investing.com
TEVA Stock Price and Chart — TASE:TEVA - TradingView
ETFs Investing in Teva Pharmaceutical Industries Limited Sponsored ADR Stocks - TradingView
TEVA Stock Quote Price and Forecast - CNN
Teva plans senior notes offering to refinance existing debt By Investing.com - Investing.com Canada
TEVA Stock Price, Quote & Chart - ChartMill
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers - TradingView
Organon & Co. (OGN) Peer Comparison – Compare with Others - Value Research
Teva announces commitment with Trump administration on Medicaid drug pricing By Investing.com - Investing.com South Africa
Teva Pharma Industries Ltd ADR (TEVA) Peer Comparison – Compare with Others - Value Research
Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy - Sahm
Teva Pharma Industries Ltd ADR (TEVA) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Teva stock hits 52-week high at 37.84 USD By Investing.com - Investing.com Australia
Teva Pharmaceutical Industries (TEVA) Could Be 10% Undervalued After FDA Accepted Ecopipam NDA - sahmcapital.com
Teva (TEVA) Wins FDA Priority Review For Pediatric Tourette Drug Candidate - Sahm
Teva receives FDA priority review for Tourette drug - grafa.com
Teva Pharmaceutical’s stock is near its yearly high; is it still a buy? - Investing.com Nigeria
TEVA PHARMACEUTICAL INDUSTRIES LTD SEC Filing (Aug 17, 2026) - Stock Titan
Teva stock hits 52-week high at 37.35 USD By Investing.com - Investing.com Nigeria
Teva stock hits 52-week high at 37.35 USD - Investing.com
Moody’s upgrades Teva rating to investment grade on debt cuts By Investing.com - Investing.com Canada
Teva Pharmaceutical Industries (TEVA) Lifts Outlook On Earnings As Valuation Debate Stays Open - Sahm
Teva (TEVA) Is Up 8.8% After Raising 2026 Guidance And Highlighting Innovative Drug Momentum - Sahm
Dear Teva Pharmaceutical Stock Fans, Mark Your Calendars for September 14 - Yahoo Finance
Teva Earnings: Innovation Engine Continues Firing and Supports Our Increased Moat Rating - Morningstar
July 2026's Top Stock Selections Estimated Below Intrinsic Value - Sahm
Teva Pharmaceutical Industries (TEVA) Raises Revenue Guidance, Is The 15% Undervaluation Still There? - Sahm
Earnings call transcript: Teva’s Q2 2026 revenue beats, shares rise premarket - Investing.com
Why Is Teva (NYSE:TEVA) Making NYSE Composite Headlines? - Kalkine Media
Daily Brief Health Care: Apnimed, Chugai Pharmaceutical, Equifax Inc, Royalty Pharma , Startline, Surgery Partners, Teva Pharmaceutical Sp Adr, Thermo Fisher Scientific Inc and more - Smartkarma
Teva Pharmaceutical Industries Limited Sponsored ADR Revenue Breakdown – BX:TEV - TradingView
Does Teva Pharmaceutical Industries (NYSE:TEVA) Still Look Undervalued After A 260% Run? - Sahm
What Teva Pharmaceutical Industries (TEVA)'s TEV‑408 Vitiligo Data and Funding Deal Means For Shareholders - Sahm
MINT,TEVA Volatility & Greeks - Finviz
Teva Pharmaceutical Industries (TEVA) Advances TEV 408, Is The Stock Still Cheap? - Sahm
Finanzdaten der Teva Pharmaceutical Industries Ltd Adr-Aktie (TEVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):